Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 8 of 8 results for valsartan

  1. Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)

    Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction.

    Technology appraisal guidance
    Published
    27 April 2016
    View recommendations

    Sections for TA388

  2. Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)

    Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.

    Technology appraisal guidance
    Published
    24 February 2021
    View recommendations

    Sections for TA679

  3. Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]

    In development Reference number: GID-TA11662 Expected publication date:  25 February 2026

    Technology appraisal guidance
    In development

  4. Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)

    Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with reduced ejection fraction in adults.

    Technology appraisal guidance
    Published
    9 March 2022
    View recommendations

    Sections for TA773

  5. Sacubitril valsartan for treating chronic heart failure with reduced ejection fraction in people under 18 years [TSID10350]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Chronic heart failure in adults (QS9)

    This quality standard covers assessing, diagnosing and managing chronic heart failure in adults (aged 18 and over). It describes high-quality care in priority areas for improvement. Statements cover adults with chronic heart failure with reduced ejection fraction and adults with chronic heart failure with preserved ejection fraction, unless otherwise stated.

    Quality standard
    Last updated
    3 September 2025
    View quality statements

    Sections for QS9

  7. Sacubitril valsartan for treating chronic heart failure with preserved ejection fraction [ID1606]

    Discontinued Reference number: GID-TA11257

    Technology appraisal guidance
    Discontinued

  8. Hypertension in adults. Patient decision aid on how do I control my blood pressure? Lifestyle options and choice of medicines

    medicines commonly end in 'artan' (for example, candesartan, losartan and valsartan). CCB stands for 'calcium channel blocker'. The...